Elevated use of cannabis, nicotine among U. S. adults continues into 2025
That matters because biology becomes more informative when an observed effect begins to look like a mechanism rather than an isolated pattern.
Key points
- Focus: That matters because biology becomes more informative when an observed effect begins to look like a mechanism rather than an isolated pattern
- Detail: separate announcement from evidence
- Editorial reading: institutional release, useful as a primary source but not independent validation.
National. survey suggests that use of. alcohol, cigarettes, and other substances. remains. low. The institutional report frames the development in practical terms and ties it to the broader mission or observing effort.
That matters because biology becomes more informative when an observed effect begins to look like a mechanism rather than an isolated pattern. The gap between identifying a correlation in biological data and understanding the causal chain that produces it is routinely underestimated, and the history of biomedical research is populated with associations that collapsed when the mechanism was sought and not found. A result that comes with a proposed mechanism, even a partial one, is more useful than a purely descriptive finding because it generates testable predictions that can narrow the hypothesis space. In 2025, adults in the United States reported using cannabis at or near record-high levels, continuing a long-term trend of increasing use. Among adults ages 19 to 65 supported by the National Institutes of Health (NIH) since its inception in 1976.
Some results bucked trends, however, such as a slight increase in self-reported heroin use among young adults aged 19 to 30, marking the first significant uptick and highest level. Adults in early midlife (35 to 50 years old) reported significantly higher rates of daily cannabis use than last year, increasing from 6.6% in 2024 to 8.5% in 2025.
Reported use of nicotine pouches over the past 12 months among all adults more than doubled since 2023 when the panel first included questions about these products. Rates of cigarette smoking over the past 30 days ranged from 8.3% of young adults to 10.6% of adults in late midlife (55 to 65 years old).
Likewise, nonmedical use of sleeping medications in the past 12 months for the same age group significantly increased from 2.0% in 2024 to 3.0% the following year. Another significant change, also among young adults, was a decrease in psychedelics use over the past year, from 8.9% in 2024 to 7.2% in 2025.
The broader interest lies in whether the reported effect points toward a real mechanism and not merely a reproducible but unexplained association. Biology has learned from decades of biomarker failures that correlation, even robust correlation, is not a substitute for mechanistic understanding. A pathway that can be traced from molecular interaction to cellular response to organismal phenotype provides a far stronger foundation for intervention than a statistical association discovered in a large dataset, however well the statistics are done.
High school graduates over the past 50 years, the MTF Longitudinal Panel Study has obtained data from more than 120, 000 individuals who originally participated in the larger. The 2025 panel results are available online from the University of Michigan.
Because the account originates with NIH News Releases, it functions best as a primary institutional report that is close to the data and operations, not as independent scientific validation. Institutional communications are produced by organizations with legitimate interests in presenting their work in a favorable light, which does not make them unreliable but does make them partial. Details that complicate the narrative, including instrument limitations, unexpected failures and results below projections, tend to be minimized relative to progress messages. Technical documentation and peer-reviewed publications, where they exist, provide the complementary layer that institutional releases cannot substitute.
The next step is to test whether the effect repeats across different methods, cell types, model organisms and experimental conditions. Reproducibility is the first test, but mechanistic dissection is the second, and a result that passes both has a substantially better chance of translating into something clinically or biotechnologically useful. The path from a laboratory finding to an applied outcome typically takes a decade or more, and most findings do not complete it; the current result sits at the beginning of that process.
Original source: NIH News Releases